76 results about "H1n1 virus" patented technology

Described herein is the generation of optimized H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H1N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on selected H1N1 viruses isolated from 1918-2012. Provided herein are optimized H1N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.

The invention discloses a novel kit for fluorescence quantitative PCR detection of influenza A H1N1 viruses, containing a primer, a probe, Taqman 2*universal PRC master mix, 40*multi scribe<TM> and RNase inhibitor mix and nuclease-free water. The primer and the probe have the advantages of good detecting specificity and high sensitivity so that the kit is particularly suitable for the influenza AH1N1 which breaks out at present and has no cross reaction with the Avian flu, swine flu and common seasonal flu and has lower cost.

The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of influenza virus infections. In particular, these antibodies may neutralize or limit the replication of H1N1 influenza virus. Also disclosed are improved methods for producing such monoclonal antibodies.

An antibody, or a binding fragment of the antibody, against H1N1 virus, includes a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region contains complementarity determining regions (CDR) that have the amino acid sequences of SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7; and wherein the light chain variable region contains complementarity determining regions that have the amino acid sequences of SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10. A method for treating or preventing H1N1 infection in a subject includes administering to the subject theantibody or the binding fragment of the antibody.

The invention relates to a constant-temperature amplification detection kit of an A(H1N1) virus and a detection method thereof. The kit comprises an RNA (Ribonucleic Acid) extracting solution, an A(H1N1) virus nucleic acid constant-temperature amplification reaction solution, A(H1N1) virus positive control and A(H1N1) virus negative control. The detection kit has high specificity, high sensitivity and high reaction speed, i.e. only two hours are needed from sample processing to detection finishing of a single sample; the sample detection of high flux and low flux can be simultaneously satisfied, and complicated instruments are not needed in the whole reaction process.

The invention belongs to the field of zoonosis researches, and relates to a method for preparing a vaccine of zoonosis. In the method, an HA gene in a cDNA sequence of a type A H1N1 California virus strain (A/California/08/2009(H1N1)) is selected as a research content; the method comprises the following steps of: firstly, analyzing a sequence of the part of an HA protein leaked outside an envelope according to structural biology software; secondly, selecting a part with high immunogenicity according to an antigenic analysis, and constructing a prokaryotic expression vector pGEX-6P-1-HA by using a genetic fragment obtained through a gene synthesis method; and thirdly, converting a masculine recombinant plasmid into Escherichia coli to obtain a recombinant strain (Escherichia coli BL21 rosseta/pGEX-6P-1-HA truncated protein). Through a plurality of chromatography methods, a purified HA truncated protein of the H1N1 is obtained; and by utilizing the expression vector and an adjuvant together to immune organisms, the protective effect on the H1N1 virus is achieved.

Disclosed are: a primer set enabling the specific detection, by an isothermal amplification method, of an influenza A virus, an influenza A subtype H3 virus, an influenza A subtype pdm H1N1 virus, and an influenza B virus; a composition or a kit comprising the same; and a method for detecting influenza viruses by using the same. The primers and the method, according to the present application, can detect, in a rapid manner and with high sensitivity and specificity, whether influenza virus infection occurs, and enable detection without separate treatments after the completion of the amplification, thereby improving convenience.

The invention belongs to the field of microbial virology and provides a swine influenza A H1N1 virus. The virus contains eight fragments, namely HA, NA, NP, PB1, PB2, PA, NS and M, wherein the nucleotide sequences of the eight fragments are shown by the sequences from No.1 to No.8 in a nucleotide sequence table in the description in turn. In the invention, by separate culture of a nasopharyngeal swab sample of a healthy pig, differential item functioning (DIF) and reverse transcription-polymerase chain reaction (RT-PCR) identification and the comparison of full sequences of 8 genes of the virus, a virus is obtained and verified to be a swine influenza A H1N1 virus strain. The swine influenza A H1N1 virus strain is named A/swine/Zhejiang/26/2009(H1N1), with a collection number of CCTCC No.V201016. The strain obtained by the invention supplies valuable genetic information of swine influenza A virus in China, has a great significance for completing a system for monitoring the infection caused by the pathogen and can be used for preparing a reagent for quickly diagnosing infection with the influenza A H1N1 virus.

The invention discloses application of an influenza treating medicine composition in preparation of antiviral medicine. The medicine composition is prepared from, by weight, 1-9 parts of ephedra, 1-9 parts of mint, 1-9 parts of periostracum cicada, 1-20 parts of honeysuckles, 2-20 parts of scutellaria baicalensis, 2-18 parts of semen armeniacae amarae, 1-9 parts of thunberg fritillary bulb, 1-9 parts of platycodon grandiflorum and 1-9 parts of liquorice. The raw materials are taken, conventional auxiliary materials are added, and clinically-acceptable tablets, granules, pills, capsules, dropping pills, soft capsules, slow-release preparations, oral liquid preparations or freeze-dried powder injections are prepared according to the conventional process; new application is developed, and new medicine is provided for treating infection of viruses RSV, EV71, COX-B3 and H1N1.

The invention relates to an H1N1 influenza virus detection method and a kit thereof. According to the invention, a simple and rapid chemical coupling method is utilized to realize efficient capture ofan inactivated complete H1N1 influenza virus; and a DNA aptamer capable of specifically recognizing the inactivated A-type H1N1 virus is used as a recognition probe to achieve specific recognition ofthe virus, and finally quantitative detection of the inactivated complete H1N1 influenza virus is achieved through real-time quantitative PCR. A detection limit is 1ng/L, and the kit has no responseto other viruses and has good specificity. Colorimetric detection of the H1N1 virus can be achieved by combining with nanogold, and the detection limit is 1 ng/L. According to the method, the completeinactivated virus serves as a target, the low-cost DNA aptamer serves as a recognition molecule, and advantages of good safety and low cost are possessed. Moreover, the method and the kit are high insensitivity and good in specificity, are successfully used for detecting the H1N1 in a throat swab sample, and have a very good clinical application value.

Belonging to the field of traditional Chinese medicines, the invention discloses application of Forsythoside A in preparation of an anti-influenza A H1N1 virus medicine and a preparation thereof. In vivo pharmacodynamic experimental study on the Forsythoside A provided in the invention in treatment of respiratory virus infection and in vitro anti-respiratory virus pharmacodynamic experimental study on the Forsythoside A show that the Forsythoside A has an obvious inhibiting effect on influenza A H1N1 viruses.

A mugwort pill containing a 95% ethanol extract of wormwood having an inactivation power with respect to a novel swine-origin influenza virus and an avian influenza virus is disclosed. In more details, the conventional mugwort pill is prepared by a hot water extraction method and has 0.8% of crude fat component; however the ethanol extract mugwort crude fat of the present invention is 11.6%, in particular the crude fat component is 14.5 times higher, and the novel swine-origin influenza virus (H1N1) can be inactivated 99.99%, and it has a good disinfection effect to an avian influenza virus (H9N2). When a mugwort pill containing a 95% ethanol extract of wormwood having an inactivation power with respect to a novel swine-origin influenza virus and an avian influenza virus is administrated to people or fowls, the people or fowls can have immunity with respect to a novel swine-origin influenza virus and an avian influenza virus.

The invention provides a fluorescent RT-RAA primer for detecting an A(H1N1) virus by using a reverse transcription recombinase mediated nucleic acid amplification technique, a fluorescent probe, and an application of the fluorescent RT-RAA primer and the fluorescent probe in detecting the A(H1N1) influenza virus. By adopting the fluorescent RT-RAA primer and the fluorescent probe, the A(H1N1) influenza virus in a throat swab sample can be rapidly and quantitatively detected, detection can be implemented at normal temperature of 39 DEG C, diagnosis results can be obtained within 20 minutes, andthe detection time is greatly shortened; the fluorescent RT-RAA primer and the fluorescent probe are respectively good in specificity and relatively high in sensitivity, rapid diagnosis and whole monitoring on epidemic situations can be met, and time for diagnosing and treating epidemic situations at an early stage, reducing the case fatality rate and controlling the epidemic situations is achieved.

The invention relates to the field of molecular biological detection and discloses an amplifying system and method for detecting H1N1 virus RNA. The amplifying system comprises Tris buffer liquid, magnesium acetate, potassium chloride, dithiothreitol, polyethylene glycol, ATP, dNTPs, phosphocreatine, recombinase, singe-strand binding protein, UvsY protein, exonuclease, fluorescent probe, DNA polymerase, revertase, RNA enzyme inhibitor and H1N1 virus specificity primer. The method includes: mixing the amplifying system with H1N1 virus RNA, performing equal-temperature amplifying, and using a fluorescent probe to detect an amplifying product in real time. The method is simple to operate, instruments are minimized and convenient to carry, and the amplifying system is short in amplifying time, high in specificity and sensitivity and suitable for basic-level and on-site detection.